Evaxion Biotech A/S (EVAX) Scheduled to Post Quarterly Earnings on Thursday

Posted by Dante Gardener on Oct 29th, 2024

Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, October 31st. Analysts expect Evaxion Biotech A/S to post earnings of ($0.12) per share for the quarter.

Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.14). The firm had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.10 million. During the same period in the prior year, the company earned ($2.10) earnings per share. On average, analysts expect Evaxion Biotech A/S to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evaxion Biotech A/S Stock Performance

Evaxion Biotech A/S stock traded up $0.13 during midday trading on Tuesday, reaching $2.97. The stock had a trading volume of 1,690 shares, compared to its average volume of 232,664. The firm has a market capitalization of $16.57 million, a PE ratio of -1.26 and a beta of -0.26. The company has a quick ratio of 2.80, a current ratio of 2.80 and a debt-to-equity ratio of 7.99. The firm’s 50-day moving average price is $2.99 and its 200 day moving average price is $3.22. Evaxion Biotech A/S has a 12 month low of $2.26 and a 12 month high of $13.61.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a research report on Thursday, September 26th.

View Our Latest Report on Evaxion Biotech A/S

Evaxion Biotech A/S Company Profile

(Get Free Report)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.